LGVN

Year:

Only show posts with narrations

LGVN Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference®

7 upvotes

2 upvotes

Title	Upvotes	Mark as read	Favorited	Rating	Add to a list
LGVN Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference®	7
Longeveron Inc. (NASDAQ: LGVN) is actively seeking partnerships and funding opportunities to advance its Alzheimer's Disease program.	2